Isradipine, L-type Ca2+ channel blocker

Be the first to review this product! Submit a review

|

(3 Publications)

MW 371.4 Da, Purity >98%. L-type Ca2+ channel blocker. Achieve your results faster with highly validated, pure and trusted compounds.

View Alternative Names

(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, 1,8-cineole 2-exo-monooxygenase, 2700049B16Rik, 3110031N04Rik, ABC member 16, MDR/TAP subfamily, ABC16, ABCB1, ABCBB_HUMAN, AIS, ANDR_HUMAN, AR, AR8, ASRT2, ATP binding cassette sub family B (MDR/TAP) member 11, ATP-binding cassette sub-family B member 11, Albendazole monooxygenase, Albendazole sulfoxidase, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Aryl hydrocarbon hydroxylase, BK channel, BK channel beta subunit, BK channel subunit beta-1, BK channel subunit beta-2, BK channel subunit beta-4, BKCA alpha, BKCA alpha subunit, BKTM, BKbeta, BKbeta1, BKbeta2, BKbeta4, BRIC2, BXR, Bile salt export pump, Bsep, CAC1C_HUMAN, CAC1D_HUMAN, CACH 2, CACH3, CACN 2, CACN4, CACNA 1D, CACNL1A1, CACNL1A2, CAPC, CCHL1A1, CCHL1A2, CP 12, CP1A2_HUMAN, CP2C9_HUMAN, CP33, CP34, CP3A4_HUMAN, CPC12, CPC8, CPC9, CPCJ, CYP1A2, CYP2C, CYP2C10, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIA2, CYPIIC9, CYPIIIA3, CYPIIIA4, CaV1.2, Calcium activated potassium channel beta 4 subunit, Calcium activated potassium channel subfamily M subunit beta 1, Calcium activated potassium channel subfamily M subunit beta 2, Calcium activated potassium channel subfamily M subunit beta 4, Calcium channel, Calcium channel L type alpha 1 polypeptide isoform 1 cardiac muscle, Calcium channel L type alpha 1 polypeptide isoform 2, Calcium channel cardic dihydropyridine sensitive alpha 1 subunit, Calcium channel neuroendocrine/brain type alpha 1 subunit, Calcium channel voltage dependent L type alpha 1, Calcium channel voltage dependent L type alpha 1C subunit, Calcium channel voltage dependent L type alpha 1D subunit, Calcium-activated potassium channel, Calcium-activated potassium channel subunit alpha-1, Calcium-activated potassium channel subunit beta, Calcium-activated potassium channel subunit beta-1, Calcium-activated potassium channel subunit beta-2, Calcium-activated potassium channel subunit beta-4, Cav1.3, Charybdotoxin receptor subunit beta-1, Charybdotoxin receptor subunit beta-2, Charybdotoxin receptor subunit beta-4, Cytochrome P(3)450, Cytochrome P-450MP, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 4, Cytochrome P450 HLp, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 NF-25, Cytochrome P450 PB-1, Cytochrome P450 family 1 polypeptide 2, Cytochrome P450 family 1 subfamily A polypeptide 2, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily I aromatic compound inducible polypeptide 2, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450, family 2, subfamily C, polypeptide 9, Cytochrome P450-P3, Cytochrome P450-PCN1, Cytokeratin-associated protein in cancer, DHPR alpha 1, DHPR alpha 1 subunit, DHTR, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), Dioxin inducable P3 450, Drosophila slowpoke like, G protein coupled receptor 154, G protein coupled receptor PGR14, G protein coupled receptor for asthma susceptibility, GPR 154, GPRA, Glucocorticoid inducible P450, HLP, HUMARA, HYSP1, Hbeta1, Hbeta2, Hbeta3, Hbeta4, K(VCA)alpha, K(VCA)beta, K(VCA)beta-1, K(VCA)beta-2, K(VCA)beta-4, KCMA1_HUMAN, KCMB1_HUMAN, KCMB2_HUMAN, KCMB4_HUMAN, KCNMA, KCNMA1, KCNMB 1, KCNMB 2, KCa1.1, KD, Kennedy disease (KD), L type, LQT8, LRC26_HUMAN, Large conductance Ca2+ activated K+ channel beta 1 subunit, Large conductance Ca2+ activated K+ channel beta2 subunit, Large conductance calcium activated potassium channel beta 2 subunit, Large conductance calcium dependent potassium ion channel beta 4 subunit, Leucine-rich repeat-containing protein 26, Lrrc26, MGC126680, MGC149605, MGC22431, MGC57945, MGC88320, MVTR, Maxi K channel, Maxi K channel beta subunit, Maxi K channel subunit beta-1, Maxi K channel subunit beta-2, Maxi K channel subunit beta-4, Maxi Potassium channel alpha, MaxiK, MaxiK channel beta 2 subunit, Microsomal monooxygenase, NF 25, NPSR, NR1B1, NR1I2_HUMAN, NR3C4, Neuropeptide S receptor, Neuropeptide S receptor 1, Nifedipine oxidase, Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein, Nuclear receptor subfamily 1 group B member 1, Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form, ONR 1, OTTHUMP00000020135, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, P(3)450, P3 450, P450 4, P450 III steroid inducible, P450 MP, P450 P3, P450 PB 1, P450 PCN1, P450 form 4, P450(PA), P450, family III, P450C2C, P450C3, P450IIC19, P450IIC9, PAR, PAR q, PASNA, PFIC 2, PGR 14, PGY4, PRR, Potassium large conductance calcium activated channel subfamily M beta member 1, Potassium large conductance calcium activated channel subfamily M beta member 2, Potassium large conductance calcium activated channel subfamily M beta member 4, Pregnane X receptor, Quinine 3-monooxygenase, RAR, RAR-alpha, RARA_HUMAN, RARalpha1, Retinoic acid nuclear receptor alpha variant 1, Retinoic acid nuclear receptor alpha variant 2, Retinoic acid receptor alpha, Retinoic acid receptor alpha polypeptide, S-mephenytoin 4-hydroxylase, SAKCA, SANDD, SBMA, SLO, SMAX1, SXR, Sister of P glycoprotein, Slo homolog, Slo-alpha, Slo-beta, Slo-beta-1, Slo-beta-2, Slo-beta-4, Slo1, Slowpoke homolog, Spgp, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid and xenobiotic receptor, TFM, TS, Taurochenodeoxycholate 6-alpha-hydroxylase, Testicular Feminization (TFM), VRR 1, Vasopressin receptor related receptor 1, Voltage dependent L type calcium channel alpha 1C subunit, Voltage gated L type calcium channel Cav1.2 alpha 1 subunit, splice variant 10*, Voltage gated calcium channel alpha 1 subunit, Voltage gated calcium channel alpha subunit Cav1.2, Voltage gated calcium channel alpha subunit Cav1.3, Voltage-dependent L-type calcium channel subunit alpha-1C, Voltage-dependent L-type calcium channel subunit alpha-1D, Voltage-gated calcium channel subunit alpha Cav1.2, Voltage-gated calcium channel subunit alpha Cav1.3, Xenobiotic monooxygenase, alpha-1 polypeptide, androgen receptor splice variant 4b, bA350O14.10, cardiac muscle, cytochrome P-450 S-mephenytoin 4-hydroxylase, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, cytokeratin-associated protein, flavoprotein-linked monooxygenase, hSlo, hslo beta, isoform 1, isoform 2, nps receptor, pregnane X nuclear receptor variant 2, progressive familial intrahepatic cholestasis 2, subfamily M subunit alpha-1, subfamily M subunit beta-1, subfamily M subunit beta-2, subfamily M subunit beta-4